Gliomas are central nervous system tumors that primarily occur in the brain and arise from glial cells. Gliomas include the most common malignant brain tumor in adults known as grade IV astrocytoma, or glioblastoma (GBM). GBM is a deadly disease for which the most significant advances in treatment offer an improvement in survival of only ∼2 months.
Critical Issues:
To develop novel treatments and improve patient outcomes, we and others have sought to determine the role of molecular signals in gliomas.
Recent Advances:
One signaling molecule that mediates important biologies in glioma is the free radical nitric oxide (NO). In glioma cells and the tumor microenvironment, NO is produced by three isoforms of nitric oxide synthase (NOS), NOS1, NOS2, and NOS3. NO and NOS affect glioma growth, invasion, angiogenesis, immunosuppression, differentiation state, and therapeutic resistance.
Future Directions:
These multifaceted effects of NO and NOS on gliomas both in vitro and in vivo suggest the potential of modulating the pathway for antiglioma patient therapies. Antioxid. Redox Signal. 26, 986–999.
Get full access to this article
View all access options for this article.
References
1.
BadnW, HegardtP, FellertMA, DarabiA, EsbjornssonM, SmithKE, JanelidzeS, SalfordLG, VisseE, and SiesjoP. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells. Scand J Immunol, 65: 289–297, 2007.
2.
BadnW, VisseE, DarabiA, SmithKE, SalfordLG, and SiesjoP. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. J Immunol, 179: 4231–4238, 2007.
3.
BakshiA, NagTC, WadhwaS, MahapatraAK, and SarkarC. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J Neurol Sci, 155: 196–203, 1998.
4.
BaoS, WuQ, McLendonRE, HaoY, ShiQ, HjelmelandAB, DewhirstMW, BignerDD, and RichJN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444: 756–760, 2006.
5.
BaoS, WuQ, SathornsumeteeS, HaoY, LiZ, HjelmelandAB, ShiQ, McLendonRE, BignerDD, and RichJN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res, 66: 7843–7848, 2006.
6.
BihorelS, CamenischG, GrossG, LemaireM, and ScherrmannJM. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. Drug Metab Dispos, 34: 1945–1949, 2006.
7.
BlackburnRV, GaloforoSS, BernsCM, MotwaniNM, CorryPM, and LeeYJ. Differential induction of cell death in human glioma cell lines by sodium nitroprusside. Cancer, 82: 1137–1145, 1998.
8.
BoksteinF, ShpigelS, and BlumenthalDT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer, 112: 2267–2273, 2008.
BroholmH, RubinI, KruseA, BraendstrupO, SchmidtK, SkriverEB, and LauritzenM. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol, 22: 273–281, 2003.
11.
BuieLW and ValgusJM. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother, 42: 1486–1490, 2008.
12.
CharlesN, OzawaT, SquatritoM, BleauAM, BrennanCW, HambardzumyanD, and HollandEC. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell, 6: 141–152, 2010.
13.
ChinK, KurashimaY, OguraT, TajiriH, YoshidaS, and EsumiH. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene, 15: 437–442, 1997.
14.
ChinotOL, WickW, MasonW, HenrikssonR, SaranF, NishikawaR, CarpentierAF, Hoang-XuanK, KavanP, CerneaD, BrandesAA, HiltonM, AbreyL, and CloughesyT. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med, 370: 709–722, 2014.
15.
CobbsCS, BrenmanJE, AldapeKD, BredtDS, and IsraelMA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res, 55: 727–730, 1995.
16.
CohenMH, ShenYL, KeeganP, and PazdurR. FDA drug approval summary: bevacizumab (Avastin®) as treatment of recurrent glioblastoma multiforme. Oncologist, 14: 1131–1138, 2009.
17.
ColasantiM, PersichiniT, FabriziC, CavalieriE, VenturiniG, AscenziP, LauroGM, and SuzukiH. Expression of a NOS-III-like protein in human astroglial cell culture. Biochem Biophys Res Commun, 252: 552–555, 1998.
18.
de VeraME, ShapiroRA, NusslerAK, MudgettJS, SimmonsRL, MorrisSMJr., BilliarTR, and GellerDA. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A, 93: 1054–1059, 1996.
19.
DirksPB. Glioma migration: clues from the biology of neural progenitor cells and embryonic CNS cell migration. J Neurooncol, 53: 203–212, 2001.
20.
DirksPB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol, 26: 2916–2924, 2008.
21.
DirksPB. Brain tumor stem cells: the cancer stem cell hypothesis writ large. Mol Oncol, 4: 420–430, 2010.
22.
DoblasS, SaundersD, KshirsagarP, PyeQ, OblanderJ, GordonB, KosankeS, FloydRA, and TownerRA. Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic Biol Med, 44: 63–72, 2008.
23.
DongH, SiuH, LuoL, FangX, JinL, and XiongM. Investigation gene and microRNA expression in glioblastoma. BMC Genomics, 11Suppl 3: S16, 2010.
24.
DresemannG. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol, 16: 1702–1708, 2005.
25.
EllieE, LoiseauH, LafondF, ArsautJ, and Demotes-MainardJ. Differential expression of inducible nitric oxide synthase mRNA in human brain tumours. Neuroreport, 7: 294–296, 1995.
26.
ErdamarS, BagciP, OzB, and DiricanA. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON, 11: 213–216, 2006.
27.
EspositoG, IzzoAA, Di RosaM, and IuvoneT. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem, 78: 835–841, 2001.
28.
EsumiH, OguraT, KurashimaY, AdachiH, HokariA, and WeiszA. Implication of nitric oxide synthase in carcinogenesis: analysis of the human inducible nitric oxide synthase gene. Pharmacogenetics, 5 Spec No: S166–S70, 1995.
29.
EylerCE, WuQ, YanK, MacSwordsJM, Chandler-MilitelloD, MisuracaKL, LathiaJD, ForresterMT, LeeJ, StamlerJS, GoldmanSA, BredelM, McLendonRE, SloanAE, HjelmelandAB, and RichJN. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell, 146: 53–66, 2011.
30.
FeinsteinDL, GaleaE, and ReisDJ. Suppression of glial iNOS expression by tyrosine kinase inhibitorsa. Ann N Y Acad Sci, 738: 325–328, 1994.
31.
FeinsteinDL, MurphyP, SharpA, GaleaE, GavrilyukV, and WeinbergG. Local anesthetics potentiate nitric oxide synthase type 2 expression in rat clial cells. J Neurosurg Anesthesiol, 13: 99–105, 2001.
32.
FeinsteinDL, ReisDJ, and RegunathanS. Inhibition of astroglial nitric oxide synthase type 2 expression by idazoxan. Mol Pharmacol, 55: 304–308, 1999.
33.
FloydRA, ChandruHK, HeT, and TownerR. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem, 11: 373–379, 2011.
34.
FujisawaH, OguraT, HokariA, WeiszA, YamashitaJ, and EsumiH. Inducible nitric oxide synthase in a human glioblastoma cell line. J Neurochem, 64: 85–91, 1995.
35.
FullerGN and ScheithauerBW. The 2007 revised World Health Organization (WHO) classification of tumours of the central nervous system: newly codified entities. Brain Pathol, 17: 304–307, 2007.
36.
GarteiserP, DoblasS, WatanabeY, SaundersD, HoyleJ, LernerM, HeT, FloydRA, and TownerRA. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Reson Imaging, 31: 796–806, 2010.
37.
GiannopoulouE, RavazoulaP, KalofonosH, MakatsorisT, and KardamakisD. Expression of HIF-1α and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo, 20: 421–425, 2006.
38.
GilbertMR. Renewing interest in targeting angiogenesis in glioblastoma. Lancet Oncol, 15: 907–908, 2014.
39.
HaagD, ZipperP, WestrichV, KarraD, PflegerK, ToedtG, BlondF, DelhommeN, HahnM, ReifenbergerJ, ReifenbergerG, and LichterP. Nos2 inactivation promotes the development of medulloblastoma in Ptch1(+/−) mice by deregulation of Gap43–dependent granule cell precursor migration. PLoS Genet, 8: e1002572, 2012.
40.
HahnH, WojnowskiL, SpechtK, KapplerR, Calzada-WackJ, PotterD, ZimmerA, MüllerU, SamsonE, Quintanilla-MartinezL, and ZimmerA. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem, 275: 28341–28344, 2000.
41.
HanahanD and WeinbergRA. Hallmarks of cancer: the next generation. Cell, 144: 646–674, 2011.
42.
HaraH, HuangPL, PanahianN, FishmanMC, and MoskowitzMA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab, 16: 605–611, 1996.
43.
HeT, DoblasS, SaundersD, CasteelR, LernerM, RitcheyJW, SniderT, FloydRA, and TownerRA. Effects of PBN and OKN007 in rodent glioma models assessed by 1H MR spectroscopy. Free Radic Biol Med, 51: 490–502, 2011.
44.
HegardtP, WidegrenB, and SjögrenH-O. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol, 200: 116–127, 2000.
45.
HjelmelandAB, WuQ, HeddlestonJM, ChoudharyGS, MacSwordsJ, LathiaJD, McLendonR, LindnerD, SloanA, and RichJN. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ, 18: 829–840, 2011.
46.
HokariA, ZeniyaM, and EsumiH. Cloning and functional expression of human inducible nitric oxide synthase (NOS) cDNA from a glioblastoma cell line A-172. J Biochem, 116: 575–581, 1994.
47.
HottingerAF, StuppR, and HomicskoK. Standards of care and novel approaches in the management of glioblastoma multiforme. Chin J Cancer, 33: 32–39, 2014.
48.
HwangSY, YooBC, JungJW, OhES, HwangJS, ShinJA, KimSY, ChaSH, and HanIO. Induction of glioma apoptosis by microglia-secreted molecules: the role of nitric oxide and cathepsin B. Biochim Biophys Acta, 1793: 1656–1668, 2009.
49.
IwataS, NakagawaK, HaradaH, OkaY, KumonY, and SakakiS. Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors. Neurosurgery, 45: 24–28; discussion 29, 1999.
50.
JanigroD, WestGA, NguyenTS, and WinnHR. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res, 75: 528–538, 1994.
51.
JeonHM, KimSH, JinX, ParkJB, KimSH, JoshiK, NakanoI, and KimH. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res, 74: 4482–4492, 2014.
52.
JiaW, Jackson-CookC, and GrafMR. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol, 223: 20–30, 2010.
53.
JohanssonAC, HegardtP, JanelidzeS, VisseE, WidegrenB, and SiesjöP. Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNγ-secreting rat glioma cells. J Neuroimmunol, 123: 135–143, 2002.
54.
JohnsonDR and O'NeillBP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol, 107: 359–364, 2012.
55.
KimRK, SuhY, CuiYH, HwangE, LimEJ, YooKC, LeeGH, YiJM, KangSG, and LeeSJ. Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells. Cancer Sci, 104: 1172–1177, 2013.
56.
KimY-J, HwangS-Y, HwangJ-S, LeeJ-W, OhE-S, and HanI-O. C6 Glioma cell insoluble matrix components enhance interferon-γ-stimulated inducible nitric-oxide synthase/nitric oxide production in BV2 microglial cells. J Biol Chem, 283: 2526–2533, 2008.
57.
KimuraH, WeiszA, KurashimaY, HashimotoK, OguraT, D'AcquistoF, AddeoR, MakuuchiM, and EsumiH. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood, 95: 189–197, 2000.
58.
KogiasE, OsterbergN, BaumerB, PsarrasN, KoentgesC, PapazoglouA, SaavedraJE, KeeferLK, and WeyerbrockA. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-pi-activated nitric oxide donor PABA/NO in malignant gliomas. Int J Cancer, 130: 1184–1194, 2012.
59.
KostourouV, CartwrightJE, JohnstoneAP, BoultJK, CullisER, WhitleyG, and RobinsonSP. The role of tumour-derived iNOS in tumour progression and angiogenesis. Br J Cancer, 104: 83–90, 2011.
60.
KurimotoM, EndoS, HirashimaY, HamadaH, OgiichiT, and TakakuA. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. J Neurooncol, 42: 35–44, 1999.
61.
LapidotT, SirardC, VormoorJ, MurdochB, HoangT, Caceres-CortesJ, MindenM, PatersonB, CaligiuriMA, and DickJE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367: 645–648, 1994.
62.
LiX, LiuD, LiuX, JiangW, ZhouW, YanW, CenY, LiB, CaoG, DingG, PangX, SunJ, ZhengJ, and ZhouH. CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-kappaB activation and NO production. Tumour Biol, 33: 1607–1618, 2012.
63.
LiZ, BaoS, WuQ, WangH, EylerC, SathornsumeteeS, ShiQ, CaoY, LathiaJ, McLendonRE, HjelmelandAB, and RichJN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15: 501–513, 2009.
64.
LinCH, LinYF, ChangMC, WuCH, HoYS, and LeeHM. Advanced glycosylation end products induce nitric oxide synthase expression in C6 glioma cells: involvement of a p38 MAP kinase-dependent mechanism. Life Sci, 69: 2503–2515, 2001.
65.
LinYM, JanHJ, LeeCC, TaoHY, ShihYL, WeiHW, and LeeHM. Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur J Pharmacol, 593: 1–9, 2008.
66.
LiuG, YuanX, ZengZ, TuniciP, NgH, AbdulkadirIR, LuL, IrvinD, BlackKL, and YuJS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer, 5: 1–12, 2006.
67.
LiuLB, LiuXB, MaJ, LiuYH, LiZQ, MaT, ZhaoXH, XiZ, and XueYX. Bradykinin increased the permeability of BTB via NOS/NO/ZONAB-mediating down-regulation of claudin-5 and occludin. Biochem Biophys Res Commun, 464: 118–125, 2015.
68.
LudwigHC, Feiz-ErfanI, BockermannV, Behnke-MurschJ, SchallockK, and MarkakisE. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res, 20: 299–304, 2000.
69.
LundEL, BastholmL, and KristjansenPE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res, 6: 971–978, 2000.
70.
MatsukadoK, InamuraT, NakanoS, FukuiM, BartusRT, and BlackKL. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery, 39: 125–133; discussion 133–134, 1996.
71.
MatsumotoH, TakahashiA, and OhnishiT. Nitric oxide radicals choreograph a radioadaptive response. Cancer Res, 67: 8574–8579, 2007.
72.
Mattace RasoG, EspositoE, IaconoA, PacilioM, CoppolaA, BiancoG, DianoS, CarloRD, and MeliR. Leptin induces nitric oxide synthase type II in C6 glioma cells: role for nuclear factor-κB in hormone effect. Neurosci Lett, 396: 121–126, 2006.
73.
MazzioE, BeckerA, and SolimanKFA. Characterization of neurotransmitters and dopamine attenuation of inducible nitric oxide synthase in glioma cells. J Neuroimmunol, 131: 70–82, 2002.
74.
MeachamCE and MorrisonSJ. Tumour heterogeneity and cancer cell plasticity. Nature, 501: 328–337, 2013.
75.
MeliR, RasoGM, CicalaC, EspositoE, FiorinoF, and CirinoG. Thrombin and PAR-1 acitvating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells. J Neurochem, 79: 556–563, 2001.
76.
MilitanteJD, FeinsteinDL, and SyapinPJ. Suppression by ethanol of inducible nitric oxide synthase expression in C6 glioma cells. J Pharmacol Exp Ther, 281: 558–565, 1997.
77.
MillerKJ and GonzalezHA. Serotonin 5-HT2A receptor activation inhibits cytokine-stimulated inducible nitric oxide synthase in C6 glioma cellsa. Ann N Y Acad Sci, 861: 169–173, 1998.
78.
NakanoS, MatsukadoK, and BlackKL. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res, 56: 4027–4031, 1996.
79.
NathanC. Nitric oxide as a secretory product of mammalian cells. FASEB J, 6: 3051–3064, 1992.
80.
NingarajNS, RaoM, HashizumeK, AsotraK, and BlackKL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther, 301: 838–851, 2002.
81.
NishiyaT, UeharaT, KanekoM, and NomuraY. Involvement of nuclear factor-κB (NF-κB) signaling in the expression of inducible nitric oxide synthase (iNOS) gene in rat C6 glioma cells. Biochem Biophys Res Commun, 275: 268–273, 2000.
82.
NomuraY. NF-κB activation and IκBα dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci, 68: 1695–1701, 2001.
83.
NoushmehrH, WeisenbergerDJ, DiefesK, PhillipsHS, PujaraK, BermanBP, PanF, PelloskiCE, SulmanEP, BhatKP, VerhaakRGW, HoadleyKA, HayesDN, PerouCM, SchmidtHK, DingL, WilsonRK, Van Den BergD, ShenH, BengtssonH, NeuvialP, CopeLM, BuckleyJ, HermanJG, BaylinSB, LairdPW, and AldapeK. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell, 17: 510–522, 2010.
84.
OkadaM, SatoA, ShibuyaK, WatanabeE, SeinoS, SuzukiS, SeinoM, NaritaY, ShibuiS, KayamaT, and KitanakaC. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol, 44: 591–599, 2014.
85.
PanJW, ZhanRY, TongY, ZhouYQ, and ZhangM. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma. J Zhejiang Univ Sci B, 6: 693–698, 2005.
86.
PapaevangelouE, WhitleyGS, JohnstoneAP, RobinsonSP, and HoweFA. Investigating the role of tumour cell derived iNOS on tumour growth and vasculature in vivo using a tetracycline regulated expression system. Int J Cancer, 138: 2678–2687, 2016.
87.
ParkSK and MurphyS. Duration of expression of inducible nitric oxide synthase in glial cells. J Neurosci Res, 39: 405–411, 1994.
88.
PughCW and RatcliffePJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9: 677–684, 2003.
89.
PullenNA and FillmoreHL. Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol, 96: 201–209, 2010.
90.
PuramSV, YeungCM, Jahani-AslA, LinC, de la IglesiaN, KonopkaG, Jackson-GrusbyL, and BonniA. STAT3-iNOS signaling mediates EGFRvIII-induced glial proliferation and transformation. J Neurosci, 32: 7806–7818, 2012.
91.
RattanR, GiriS, SinghAK, and SinghI. Rho a negatively regulates cytokine-mediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKα. Free Radic Biol Med, 35: 1037–1050, 2003.
92.
ReardonDA, EgorinMJ, QuinnJA, RichJN, GururanganS, VredenburghJJ, DesjardinsA, SathornsumeteeS, ProvenzaleJM, HerndonJE2nd, DowellJM, BadruddojaMA, McLendonRE, LagattutaTF, KicielinskiKP, DresemannG, SampsonJH, FriedmanAH, SalvadoAJ, and FriedmanHS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol, 23: 9359–9368, 2005.
93.
RichJN, GuoC, McLendonRE, BignerDD, WangX-F, and CounterCM. A genetically tractable model of human glioma formation. Cancer Res, 61: 3556–3560, 2001.
94.
SafdarS, PayneCA, TuNH, and TaiteLJ. Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6)-methylguanine-DNA methyltransferase activity. Biotechnol Bioeng, 110: 1211–1220, 2013.
95.
SafdarS and TaiteLJ. Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins. Int J Pharm, 422: 264–270, 2012.
96.
SanchezAC, DavisRL, and SyapinPJ. The Oct DNA motif participates in the alcohol inhibition of the inducible nitric oxide synthase gene promoter in rat C6 glioma cells. Brain Res, 1179: 16–27, 2007.
97.
ShaoC, FolkardM, MichaelBD, and PriseKM. Bystander signaling between glioma cells and fibroblasts targeted with counted particles. Int J Cancer, 116: 45–51, 2005.
98.
ShaoC, FolkardM, and PriseKM. Role of TGF-beta1 and nitric oxide in the bystander response of irradiated glioma cells. Oncogene, 27: 434–440, 2008.
99.
ShaoC, PriseKM, and FolkardM. Signaling factors for irradiated glioma cells induced bystander responses in fibroblasts. Mutat Res, 638: 139–145, 2008.
100.
ShaoC, StewartV, FolkardM, MichaelBD, and PriseKM. Nitric oxide-mediated signaling in the bystander response of individually targeted glioma cells. Cancer Res, 63: 8437–8442, 2003.
101.
ShihAH, DaiC, HuX, RosenblumMK, KoutcherJA, and HollandEC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res, 64: 4783–4789, 2004.
102.
ShinodaJ, McLaughlinKE, BellHS, SwaroopGR, YamaguchiS-I, HolmesMC, and WhittleIR. Molecular mechanisms underlying dexamethasone inhibition of iNOS expression and activity in C6 glioma cells. Glia, 42: 68–76, 2003.
103.
SimmonsML and MurphyS. Induction of nitric oxide synthase in glial cells. J Neurochem, 59: 897–905, 1992.
104.
SimmonsML and MurphyS. Cytokines regulate L-arginine-dependent cyclic GMP production in rat glial cells. Eur J Neurosci, 5: 825–831, 1993.
105.
SinghSK, HawkinsC, ClarkeID, SquireJA, BayaniJ, HideT, HenkelmanRM, CusimanoMD, and DirksPB. Identification of human brain tumour initiating cells. Nature, 432: 396–401, 2004.
106.
SolimanMK, MazzioE, and SolimanKFA. Levodopa modulating effects of inducible nitric oxide synthase and reactive oxygen species in glioma cells. Life Sci, 72: 185–198, 2002.
107.
SonodaY, OzawaT, AldapeKD, DeenDF, BergerMS, and PieperRO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res, 61: 6674–6678, 2001.
108.
SonodaY, OzawaT, HiroseY, AldapeKD, McMahonM, BergerMS, and PieperRO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res, 61: 4956–4960, 2001.
109.
StuppR, HegiME, MasonWP, van den BentMJ, TaphoornMJ, JanzerRC, LudwinSK, AllgeierA, FisherB, BelangerK, HauP, BrandesAA, GijtenbeekJ, MarosiC, VechtCJ, MokhtariK, WesselingP, VillaS, EisenhauerE, GorliaT, WellerM, LacombeD, CairncrossJG, and MirimanoffRO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Groups. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10: 459–466, 2009.
110.
StuppR, MasonWP, van den BentMJ, WellerM, FisherB, TaphoornMJB, BelangerK, BrandesAA, MarosiC, BogdahnU, CurschmannJ, JanzerRC, LudwinSK, GorliaT, AllgeierA, LacombeD, CairncrossJG, EisenhauerE, and MirimanoffRO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352: 987–996, 2005.
111.
SwaroopGR, KellyPA, BellHS, ShinodaJ, YamaguchiS, and WhittleIR. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br J Neurosurg, 14: 543–548, 2000.
112.
SyapinPJ. Ethanol inhibition of inducible nitric oxide synthase activity in C6 glioma cells. Alcohol Clin Exp Res, 19: 262–267, 1995.
113.
SyapinPJ, MilitanteJD, GarrettDK, and RenL. Cytokine-induced iNOS expression in C6 glial cells: transcriptional inhibition by ethanol. J Pharmacol Exp Ther, 298: 744–752, 2001.
114.
SyapinPJ, RendonA, HuronDR, and MilitanteJD. Effects of short chain alkanols on the inducible nitric oxide synthase in a glial cell line. Br J Pharmacol, 126: 1253–1261, 1999.
115.
TanrioverN, UluMO, IslerC, DurakH, OzB, UzanM, and AkarZ. Neuronal nitric oxide synthase expression in glial tumors: correlation with malignancy and tumor proliferation. Neurol Res, 30: 940–944, 2008.
116.
ThielVE and AudusKL. Nitric oxide and blood-brain barrier integrity. Antioxid Redox Signal, 3: 273–278, 2001.
117.
TownerRA, GillespieDL, SchwagerA, SaundersDG, SmithN, NjokuCE, KrysiakRS3rd, LarabeeC, IqbalH, FloydRA, BourneDW, AbdullahO, HsuEW, and JensenRL. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncol, 15: 330–340, 2013.
118.
TownerRA, SmithN, DoblasS, GarteiserP, WatanabeY, HeT, SaundersD, HerleaO, Silasi-MansatR, and LupuF. In vivo detection of inducible nitric oxide synthase in rodent gliomas. Free Radic Biol Med, 48: 691–703, 2010.
119.
TuettenbergJ, FriedelC, and VajkoczyP. Angiogenesis in malignant glioma—a target for antitumor therapy?. Crit Rev Oncol Hematol, 59: 181–193, 2006.
120.
TurcanS, RohleD, GoenkaA, WalshLA, FangF, YilmazE, CamposC, FabiusAW, LuC, WardPS, ThompsonCB, KaufmanA, GuryanovaO, LevineR, HeguyA, VialeA, MorrisLG, HuseJT, MellinghoffIK, and ChanTA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 483: 479–483, 2012.
121.
VenturiniG, ColasantiM, PersichiniT, FioravantiE, FedericoR, and AscenziP. Selective inhibition of nitric oxide synthase type I by clonidine, an anti-hypertensive drug. Biochem Pharmacol, 60: 539–544, 2000.
122.
VerhaakRG, HoadleyKA, PurdomE, WangV, QiY, WilkersonMD, MillerCR, DingL, GolubT, MesirovJP, AlexeG, LawrenceM, O'KellyM, TamayoP, WeirBA, GabrielS, WincklerW, GuptaS, JakkulaL, FeilerHS, HodgsonJG, JamesCD, SarkariaJN, BrennanC, KahnA, SpellmanPT, WilsonRK, SpeedTP, GrayJW, MeyersonM, GetzG, PerouCM, and HayesDN; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17: 98–110, 2010.
123.
VredenburghJJ, DesjardinsA, HerndonJE, MarcelloJ, ReardonDA, QuinnJA, RichJN, SathornsumeteeS, GururanganS, SampsonJ, WagnerM, BaileyL, BignerDD, FriedmanAH, and FriedmanHS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol, 25: 4722–4729, 2007.
124.
WangC-N, ShiaoY-J, LinY-L, and ChenC-F. Nepalolide A inhibits the expression of inducible nitric oxide synthase by modulating the degradation of IκB-α and IκB-β in C6 glioma cells and rat primary astrocytes. Br J Pharmacol, 128: 345–356, 1999.
125.
WangY, YanW, LuX, QianC, ZhangJ, LiP, ShiL, ZhaoP, FuZ, PuP, KangC, JiangT, LiuN, and YouY. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol, 90: 642–648, 2011.
126.
WeidensteinerC, ReichardtW, ShamiPJ, SaavedraJE, KeeferLK, BaumerB, WerresA, JasinskiR, OsterbergN, and WeyerbrockA. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. Nitric Oxide, 30: 17–25, 2013.
127.
WenPY and KesariS. Malignant gliomas in adults. N Engl J Med, 359: 492–507, 2008.
128.
WeyerbrockA, BaumerB, and PapazoglouA. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro. J Neurosurg, 110: 128–136, 2009.
129.
WeyerbrockA, OsterbergN, PsarrasN, BaumerB, KogiasE, WerresA, BetteS, SaavedraJE, KeeferLK, and PapazoglouA. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas. Neurosurgery, 70: 497–510; discussion 510, 2012.
130.
WeyerbrockA, WalbridgeS, SaavedraJE, KeeferLK, and OldfieldEH. Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas. Neuro Oncol, 13: 203–211, 2011.
131.
WhittleIR, CollinsF, KellyPA, RitchieI, and IronsideJW. Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochir (Wien), 138: 870–875; discussion 875–876, 1996.
132.
XuX and MalaveA. p38 MAPK, but not p42/p44 MAPK mediated inducible nitric oxide synthase expression in C6 glioma cells. Life Sci, 67: 3221–3230, 2000.
133.
YamaguchiS, BellHS, ShinodaJ, HolmesMC, WhartonSB, and WhittleIR. Glioma tumourgenicity is decreased by iNOS knockout: experimental studies using the C6 striatal implantation glioma model. Br J Neurosurg, 16: 567–572, 2002.
134.
YanX, ChengX, LiuJ, LuoD, HeX, ChenF, QinC, and WangY. Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma. Clin Invest Med, 31: E206–E211, 2008.
135.
YangD-I, YinJ-H, MishraS, MishraRAJ, and HsuCY. NO-mediated chemoresistance in C6 glioma cells. Ann N Y Acad Sci, 962: 8–17, 2002.
136.
YangJJ, YinJH, and YangDI. Nitric oxide donors attenuate clongenic potential in rat C6 glioma cells treated with alkylating chemotherapeutic agents. Neurosci Lett, 418: 106–110, 2007.
137.
YinD, WangX, KondaBM, OngJM, HuJ, SacapanoMR, KoMK, EspinozaAJ, IrvinDK, ShuY, and BlackKL. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. Clin Cancer Res, 14: 4002–4009, 2008.
138.
YuW-J, LiauS-S, ChinW-T, and ChengJ-T. Effect of serum in medium on the expression of inducible nitric oxide synthase and superoxide dismutases in cultured C6 glioma cells. Neurosci Lett, 261: 37–40, 1999.
139.
ZhangJ, PengX, WeiG, and SuD. NBPA: a cerebral ischaemic protective agent. Clin Exp Pharmacol Physiol, 26: 845–846, 1999.
140.
ZhengPP, HopWC, LuiderTM, Sillevis SmittPA, and KrosJM. Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol, 62: 40–48, 2007.
